329 related articles for article (PubMed ID: 17069059)
1. [The use of beta-interferon-1b in children and adolescents with multiple sclerosis].
Bykova OV; Kuzenkova LM; Maslova OI
Zh Nevrol Psikhiatr Im S S Korsakova; 2006; 106(9):29-33. PubMed ID: 17069059
[TBL] [Abstract][Full Text] [Related]
2. Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis.
Banwell B; Reder AT; Krupp L; Tenembaum S; Eraksoy M; Alexey B; Pohl D; Freedman M; Schelensky L; Antonijevic I
Neurology; 2006 Feb; 66(4):472-6. PubMed ID: 16505297
[TBL] [Abstract][Full Text] [Related]
3. Long-term experience with interferon beta-1b (Betaferon)in multiple sclerosis.
Arnason BG
J Neurol; 2005 Sep; 252 Suppl 3():iii28-iii33. PubMed ID: 16170497
[TBL] [Abstract][Full Text] [Related]
4. [Multiple sclerosis in children and adolescents: history and current experience of immunomodulating treatment].
Bykova OV; Maslova OI; Guseva MR; Boĭko SIu; Totolian NA; Matveeva TA; Boĭko AN
Zh Nevrol Psikhiatr Im S S Korsakova; 2004; 104(4):4-10. PubMed ID: 15270293
[TBL] [Abstract][Full Text] [Related]
5. [Effective treatment of multiple sclerosis with rebif-22 mcg in children and adolescences: results of a long-term study].
Bykova OV; Studenikin VM; Kuzenkova LM; Maslova OI; Boĭko AN
Zh Nevrol Psikhiatr Im S S Korsakova; 2006; Spec No 3():116-21. PubMed ID: 17172246
[TBL] [Abstract][Full Text] [Related]
6. [Certain problems of therapy with beta-interferon preparations].
Gusev EI; Demina TL; Boĭko AN; Khachanova NV
Zh Nevrol Psikhiatr Im S S Korsakova; 2003; (Spec No 2):98-102. PubMed ID: 12938643
[TBL] [Abstract][Full Text] [Related]
7. [Clinical efficacy and safety of long-term immunomodulating therapy with interferon beta].
Demina TL; Khachanova NV; Davydovskaia MV; Popova NF; Gusev EI
Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(4):24-6. PubMed ID: 18567192
[No Abstract] [Full Text] [Related]
8. Autoantibodies in multiple sclerosis patients before and during IFN-beta 1b treatment: are they correlated with the occurrence of autoimmune diseases?
Verdun E; Isoardo G; Oggero A; Ferrero B; Ghezzi A; Montanari E; Zaffaroni M; Durelli L;
J Interferon Cytokine Res; 2002 Feb; 22(2):245-55. PubMed ID: 11911808
[TBL] [Abstract][Full Text] [Related]
9. Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b.
Frese A; Bethke F; Lüdemann P; Stögbauer F
Neurology; 1999 Nov; 53(8):1892-3. PubMed ID: 10563657
[No Abstract] [Full Text] [Related]
10. Multiple sclerosis and interferon beta-1b, past, present and future.
Horowski R
Clin Neurol Neurosurg; 2002 Jul; 104(3):259-64. PubMed ID: 12127665
[No Abstract] [Full Text] [Related]
11. Multiple sclerosis, interferon beta-1b and depression A prospective investigation.
Feinstein A; O'Connor P; Feinstein K
J Neurol; 2002 Jul; 249(7):815-20. PubMed ID: 12140662
[TBL] [Abstract][Full Text] [Related]
12. [Cognitive disturbances and attempts of their correction in multiple sclerosis].
Shmidt TE
Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(9):54-6. PubMed ID: 16252387
[No Abstract] [Full Text] [Related]
13. The role of interferons in the treatment of multiple sclerosis.
Kelley CL
J Neurosci Nurs; 1996 Apr; 28(2):114-20. PubMed ID: 8718760
[TBL] [Abstract][Full Text] [Related]
14. [Experience in the treatment of multiple sclerosis with interferon beta in Galicia].
Romero-López J; Seijo-Martínez M; Del Campo V; Amigo-Jorrín MC; Arias M; Cortés-Laíño JA; Dapena-Bolaño D; López-González FJ; Lorenzo-González JR; Marín-Sánchez M; Muñoz-García D; Ozaita-Arteche G; Prieto JM
Rev Neurol; 2003 Dec 1-15; 37(11):1001-4. PubMed ID: 14669137
[TBL] [Abstract][Full Text] [Related]
15. Interferons in MS Treatment: report from the Canadian MS Forum symposium, 26-29 August 2004, Québec, Canada.
Duquette P
Int MS J; 2005 Apr; 12(1):33-4. PubMed ID: 15955277
[TBL] [Abstract][Full Text] [Related]
16. [Report from the Satellite Symposium: Leading the way: outstanding efficacy of interferon beta-1b right from the start. Berlin, Germany, 06.24.2002].
Cendrowski W
Neurol Neurochir Pol; 2002; 36(6):1260-3. PubMed ID: 12715704
[No Abstract] [Full Text] [Related]
17. [Betaferon in the treatment of multiple sclerosis: efficacy standards].
Totolian NA
Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(7):63-6. PubMed ID: 16117152
[No Abstract] [Full Text] [Related]
18. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis.
Montalban X; Sastre-Garriga J; Tintoré M; Brieva L; Aymerich FX; Río J; Porcel J; Borràs C; Nos C; Rovira A
Mult Scler; 2009 Oct; 15(10):1195-205. PubMed ID: 19797261
[TBL] [Abstract][Full Text] [Related]
19. Contemporary immunomodulatory therapy for multiple sclerosis.
Rudick RA
J Neuroophthalmol; 2001 Dec; 21(4):284-91. PubMed ID: 11756861
[TBL] [Abstract][Full Text] [Related]
20. [Beta interferon in multiple sclerosis: pharmacological differences].
Allain H; Bentué-Ferrer D; Schück S; Ruffault A
Rev Neurol (Paris); 1999; 155 Suppl 2():S24-30. PubMed ID: 10367322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
